AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9606737 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 29
Study 9606737 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate hemodialysis (BH)
Number of subjects: 29
Study 7618728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (9-MAC-hour)
Number of subjects: 0
Study 7618728 — intervention group
Group type: COMPARATOR
Intervention: Enflurane (9-MAC-hour)
Number of subjects: 0
Study 7618728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and Enflurane (both 9-MAC-hour)
Number of subjects: 0
Study 7618728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and Enflurane (prolonged anesthesia)
Number of subjects: 0
Study 2693064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation
Number of subjects: 10
Study 2693064 — intervention group
Group type: COMPARATOR
Intervention: Sound stimulus
Number of subjects: 10
Study 2693064 — intervention group
Group type: COMPARATOR
Intervention: Vibratory stimulation and Sound stimulus
Number of subjects: 10
Study 81588 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 132
Study 81588 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 132
Study 81588 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma globulin immunotherapy
Number of subjects: 132
Study 81588 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 30196790 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm including elevated C-reactive protein ≥30 mg/l
Number of subjects: 1088
Study 30196790 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated C-reactive protein with chest and laboratory findings
Number of subjects: 1088
Study 30196790 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified algorithm of pyrexia or elevated C-reactive protein and chest signs with infiltrates or leukocytosis
Number of subjects: 1088
Study 30196790 — intervention group
Group type: COMPARATOR
Intervention: Algorithm without elevated C-reactive protein
Number of subjects: 1088
Study 27863211 — intervention group
Group type: EXPERIMENTAL
Intervention: LC‐MS/MS method
Number of subjects: 0
Study 27863211 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche method
Number of subjects: 0
Study 25136888 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus‐eluting stent (ZES)
Number of subjects: 1391
Study 25136888 — intervention group
Group type: COMPARATOR
Intervention: XIENCE V everolimus‐eluting stent (EES)
Number of subjects: 1391
Study 22282453 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Intervention for Dual Disorders (FIDD)
Number of subjects: 108
Study 22282453 — intervention group
Group type: COMPARATOR
Intervention: Family Education (ED)
Number of subjects: 108
Study 22104026 — intervention group
Group type: EXPERIMENTAL
Intervention: Local thermal therapy with far‐infrared rays (FIR), 20 minutes per day, twice a week, for 20 sessions
Number of subjects: 43
Study 22104026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 43
Study 22104026 — intervention group
Group type: EXPERIMENTAL
Intervention: Local thermal therapy with far‐infrared rays (FIR)
Number of subjects: 43
Study 19276293 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) with 6 tasks (hand to table [front], hand to box [front], reach and retrieve, lift can, lift pencil, and fold towel)
Number of subjects: 0
Study 19276293 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 0
Study 16687913 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger diameter post
Number of subjects: 40
Study 16687913 — intervention group
Group type: COMPARATOR
Intervention: Smaller diameter post
Number of subjects: 40
Study 15300377 — intervention group
Group type: EXPERIMENTAL
Intervention: GHQ5 (General Health Questionnaire, shortened version)
Number of subjects: 450
Study 15300377 — intervention group
Group type: COMPARATOR
Intervention: FACES test (visual measure of mood)
Number of subjects: 450
Study 11406738 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa‐2b
Number of subjects: 0
Study 11406738 — intervention group
Group type: COMPARATOR
Intervention: interferon alfa‐2b
Number of subjects: 0
Study 9433596 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cM genetic map with alpha = 0.05
Number of subjects: 239
Study 9433596 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of 31 plateaus from the 2 cM screen
Number of subjects: 239
Study 9433596 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipoint analysis
Number of subjects: 239
Study 9433596 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication of two-point analysis of plateau markers in replicate 80
Number of subjects: 239
Study 9433596 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipoint analysis in replicate 80
Number of subjects: 239
Study 9433596 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustments in map density, follow-up on plateaus, and decreasing significance levels
Number of subjects: 239
Study 8438938 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal blood glucose levels
Number of subjects: 158
Study 3120758 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy (45 Gy) and chemotherapy (doxorubicin and cyclophosphamide)
Number of subjects: 86
Study 3120758 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy only
Number of subjects: 86
Study 3120758 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil)
Number of subjects: 86
Study 3120758 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and chemotherapy
Number of subjects: 86
Study 31356802 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronectomy
Number of subjects: 110
Study 31356802 — intervention group
Group type: COMPARATOR
Intervention: Traditional extraction
Number of subjects: 110
Study 29552783 — intervention group
Group type: EXPERIMENTAL
Intervention: sunitinib plus transarterial chemoembolization (SU+TACE)
Number of subjects: 104
Study 29552783 — intervention group
Group type: COMPARATOR
Intervention: sorafenib plus transarterial chemoembolization (SO+TACE)
Number of subjects: 104
Study 26992083 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent-Community Reinforcement Approach (A-CRA) and assertive continuing care (ACC)
Number of subjects: 126
Study 26992083 — intervention group
Group type: COMPARATOR
Intervention: Services as usual (SAU)
Number of subjects: 126
Study 24997747 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular multimodal drug injection
Number of subjects: 70
Study 24997747 — intervention group
Group type: COMPARATOR
Intervention: No injection
Number of subjects: 70
Study 22236504 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg metyrapone/20 mg oxazepam (low dose)
Number of subjects: 45
Study 22236504 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg metyrapone/20 mg oxazepam (high dose)
Number of subjects: 45
Study 22236504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 20332274 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (800 IU/d)
Number of subjects: 92
Study 20332274 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (2.0 g/d)
Number of subjects: 92
Study 17630547 — intervention group
Group type: COMPARATOR
Intervention: saquinavir/ritonavir 2000/100 mg o.d.
Number of subjects: 25
Study 17630547 — intervention group
Group type: EXPERIMENTAL
Intervention: saquinavir/ketoconazole 2000/400 mg o.d.
Number of subjects: 25
Study 15326114 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic stimuli at four temperatures
Number of subjects: 20
Study 15326114 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical thresholds with varying flow rates
Number of subjects: 20
Study 15326114 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thresholds with added CO2
Number of subjects: 20
Study 15326114 — intervention group
Group type: COMPARATOR
Intervention: Temperature effects on chemical thresholds
Number of subjects: 20
Study 15326114 — intervention group
Group type: COMPARATOR
Intervention: Temperature effects on mechanical discomfort thresholds
Number of subjects: 20
Study 11767814 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program related to advance care planning
Number of subjects: 284
Study 11767814 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 284
Study 9238166 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (radiotherapy)
Number of subjects: 0
Study 9238166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-containing chemotherapy
Number of subjects: 0
Study 9238166 — intervention group
Group type: EXPERIMENTAL
Intervention: New promising chemotherapy regimens and new fractionated radiation schedules
Number of subjects: 0
Study 9238166 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative therapeutic approaches (biotherapies, recombinant cytokines, antitumoral vaccine, gene therapy)
Number of subjects: 0
Study 8424702 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with pyloroplasty
Number of subjects: 79
Study 8424702 — intervention group
Group type: COMPARATOR
Intervention: Selective proximal vagotomy without pyloroplasty
Number of subjects: 79
Study 3303430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia of the intercostal nerves (one minute of direct cryotherapy to at least five intercostal nerves)
Number of subjects: 53
Study 3303430 — intervention group
Group type: COMPARATOR
Intervention: Control group (received standard care with methadone via lumbar epidural)
Number of subjects: 53
Study 29685591 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab 150 mg subcutaneously every 2 weeks
Number of subjects: 1578
Study 29685591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1578
Study 29685591 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab
Number of subjects: 1578
Study 27514633 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Plate Fixation (PF)
Number of subjects: 120
Study 27514633 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary Fixation (IMF)
Number of subjects: 120
Study 25017710 — intervention group
Group type: EXPERIMENTAL
Intervention: bacteriostatic normal saline (bNS)
Number of subjects: 19
Study 25017710 — intervention group
Group type: COMPARATOR
Intervention: normal saline (NS)
Number of subjects: 19
Study 22515282 — intervention group
Group type: EXPERIMENTAL
Intervention: restrictive oral appliance (restrict‐MMOA)
Number of subjects: 11
Study 22515282 — intervention group
Group type: EXPERIMENTAL
Intervention: free‐MMOA (full‐arch maxillary and mandibular oral appliances with no restrictions of mandibular movements)
Number of subjects: 11
Study 22515282 — intervention group
Group type: EXPERIMENTAL
Intervention: free‐MOA (conventional full‐arch flat stabilisation appliance)
Number of subjects: 11
Study 22515282 — intervention group
Group type: COMPARATOR
Intervention: baseline (no oral appliance)
Number of subjects: 11
Study 20814042 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at lactate threshold intensity for eight weeks
Number of subjects: 60
Study 20814042 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 20031796 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention (SI) with personalized risk factor screening, therapeutic lifestyle-change counseling, and progress reports to physicians
Number of subjects: 501
Study 20031796 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (CIN)
Number of subjects: 501
Study 20031796 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention (SI)
Number of subjects: 501
Study 16643361 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam administered orally 75 minutes prior to scheduled atrial shock delivery
Number of subjects: 15
Study 14657976 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Psychiatric Rating Scale (BPRS 4.0)
Number of subjects: 0
Study 14657976 — intervention group
Group type: EXPERIMENTAL
Intervention: Groningen Social Disabilities Schedule (GSDS‐II)
Number of subjects: 0
Study 11300367 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaprilat (0.5 microg/dL/min)
Number of subjects: 12
Study 11300367 — intervention group
Group type: COMPARATOR
Intervention: Enalaprilat (0.5 microg/dL/min)
Number of subjects: 12
Study 8972016 — intervention group
Group type: EXPERIMENTAL
Intervention: US formulation of Hemofil-M at a dose of 50 u/kg
Number of subjects: 12
Study 8972016 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish formulation of Hemofil-M at a dose of 50 u/kg
Number of subjects: 12
Study 8972016 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromogenic assay
Number of subjects: 12
Study 8972016 — intervention group
Group type: COMPARATOR
Intervention: One-stage clotting assay
Number of subjects: 12
Study 1458938 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. nicardipine
Number of subjects: 139
Study 1458938 — intervention group
Group type: COMPARATOR
Intervention: sodium nitroprusside
Number of subjects: 139
Study 6141750 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blocker phenoxybenzamine (10-20 mg daily)
Number of subjects: 31
Study 6141750 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alpha-blocker phenoxybenzamine (10-20 mg daily) and beta-blocker sotalol (40-80 mg daily)
Number of subjects: 31
Study 30885454 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (simulation training)
Number of subjects: 82
Study 30885454 — intervention group
Group type: COMPARATOR
Intervention: Group D (classroom training only)
Number of subjects: 82
Study 29735863 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically-cured indirect bonding resin
Number of subjects: 20
Study 29735863 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured indirect bonding resin
Number of subjects: 20
Study 29735863 — intervention group
Group type: COMPARATOR
Intervention: Direct bonding control group
Number of subjects: 20
Study 29735863 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo bond survival rates for both indirect resins
Number of subjects: 20
Study 27022607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) Group: 50 mg/kg MgSO4 intravenously in 150 mL saline
Number of subjects: 75
Study 27022607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) Group: 50 mg/kg MgSO4 in 30 mL saline injected intramuscularly
Number of subjects: 75
Study 27022607 — intervention group
Group type: COMPARATOR
Intervention: Control (C) Group: 30 mL saline injected intramuscularly
Number of subjects: 75
Study 24311723 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 519
Study 24311723 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 519
Study 21775915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) feeding
Number of subjects: 78
Study 21775915 — intervention group
Group type: COMPARATOR
Intervention: Nasojejunal (NJ) feeding
Number of subjects: 78
Study 20576667 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor learning coaching
Number of subjects: 78
Study 20576667 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental treatment
Number of subjects: 78
Study 18186675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (F, n = 49) for 12 hours before SWL
Number of subjects: 97
Study 18186675 — intervention group
Group type: COMPARATOR
Intervention: Non-fasting (NF, n = 48)
Number of subjects: 97
Study 12895267 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon A (10 MU IntronA/day for 2 weeks, followed by 10 MU/2 days for 12 weeks) + ribavirin (1-1.2 g/day)
Number of subjects: 155
Study 12895267 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon B (5 MU/day for 14 weeks) + ribavirin (1-1.2 g/day)
Number of subjects: 155
Study 12895267 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon C (5 MU/2 days for 14 weeks) + ribavirin (1-1.2 g/day)
Number of subjects: 155
Study 10907971 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 534
Study 10907971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day
Number of subjects: 534
Study 10907971 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 534
Study 10907971 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 534
Study 10907971 — intervention group
Group type: COMPARATOR
Intervention: Other dosages of HMG-CoA reductase inhibitors
Number of subjects: 534
Study 8969878 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Stimulation (AS)
Number of subjects: 40
Study 8969878 — intervention group
Group type: COMPARATOR
Intervention: Placebo Stimulation (PS)
Number of subjects: 40
Study 1427656 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 21
Study 1427656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6726981 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of activated charcoal and sorbitol
Number of subjects: 10
Study 6726981 — intervention group
Group type: COMPARATOR
Intervention: Single dose of charcoal and cathartic
Number of subjects: 10
Study 31155769 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuma longa
Number of subjects: 136
Study 31155769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 28904371 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose insulin infusion
Number of subjects: 20
Study 28904371 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose insulin infusion
Number of subjects: 20
Study 28904371 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose hydrocortisone with high insulin
Number of subjects: 20
Study 28904371 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC)
Number of subjects: 20
Study 26121535 — intervention group
Group type: EXPERIMENTAL
Intervention: Kids In Divorce Situations (KIDS) intervention
Number of subjects: 156
Study 26121535 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 156
Study 24158664 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated digital wrist manometer
Number of subjects: 100
Study 24158664 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated digital arm manometer
Number of subjects: 100
Study 24158664 — intervention group
Group type: COMPARATOR
Intervention: Calibrated aneroid control device
Number of subjects: 100
Study 22338129 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic presacral neurectomy (LPN) in addition to conventional laparoscopic resection of endometriosis lesions
Number of subjects: 64
Study 22338129 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic resection of endometriosis lesions
Number of subjects: 64
Study 19694853 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counselling programme
Number of subjects: 42
Study 19694853 — intervention group
Group type: COMPARATOR
Intervention: Ordinary counselling
Number of subjects: 42
Study 17524958 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCOVA
Number of subjects: 0
Study 17524958 — intervention group
Group type: EXPERIMENTAL
Intervention: RM with Kenward and Roger's adjustment
Number of subjects: 0
Study 17524958 — intervention group
Group type: COMPARATOR
Intervention: RM
Number of subjects: 0
Study 17287298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrabronchial administration of recombinant surfactant protein C-based surfactant preparation (Venticute)
Number of subjects: 31
Study 17287298 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treatment (Venticute)
Number of subjects: 31
Study 17287298 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation of Venticute with synthetic neutral lipid preparation
Number of subjects: 31
Study 10936812 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of sorbents in continuous plasma filtration
Number of subjects: 0
Study 10936812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific simultaneous removal of several mediators of the inflammatory cascade
Number of subjects: 0
Study 8791050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 60 mg/m2 i.v. and epirubicin 60 mg/m2 i.v. every 3 weeks for six cycles, with estramustine phosphate at 10 mg/kg p.o. in two divided daily doses during chemotherapy and until progression.
Number of subjects: 28
Study 1619006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal octreotide 2000 micrograms
Number of subjects: 15
Study 1619006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal octreotide 1000 micrograms
Number of subjects: 15
Study 1619006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal octreotide 500 micrograms
Number of subjects: 15
Study 1619006 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous octreotide 100 micrograms
Number of subjects: 15
Study 1619006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal octreotide (all doses)
Number of subjects: 15
Study 6095549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg/die
Number of subjects: 12
Study 6095549 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 2000 mg/die
Number of subjects: 12
Study 6095549 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 2000 mg/die + Pirenzepine 2 X 10 mg/die
Number of subjects: 12
Study 30137455 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2‐enriched air
Number of subjects: 90
Study 30137455 — intervention group
Group type: COMPARATOR
Intervention: Compressed room air
Number of subjects: 90
Study 30138422 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐piece
Number of subjects: 190
Study 30138422 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV
Number of subjects: 190
Study 27139523 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity treatment with liberalized goals for serum phosphorus and parathyroid hormone (PTH)
Number of subjects: 16
Study 27139523 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study 24401752 — intervention group
Group type: EXPERIMENTAL
Intervention: Social franchising program training community educators and supplying ORS plus zinc
Number of subjects: 3605